Three International Drug Developers Award $3.6 Million in Thorough QT Studies to eResearchTechnology

Three International Drug Developers Award $3.6 Million in
Thorough QT Studies to eResearchTechnology
Sponsors Include a Top-10 Pharma and Two Japan-based International
Pharmaceuticals Demonstrating Continued Global Adoption of Regulatory Guidance



PHILADELPHIA, Feb. 9  /PRNewswire-FirstCall/ -- eResearchTechnology, Inc. (eRT)
(NASDAQ:ERES), a leading provider of centralized electrocardiographic (ECG)
collection and interpretation services, announced today that it has been
awarded three Thorough QT studies valued at more than $3.6 million in cardiac
safety monitoring and services from a global top-10 drug developer and two
Japan-based international drug developers for three compounds in clinical
trials.

The awards cover three significant Thorough QT studies, for which eRT is
providing comprehensive support, including provision of digital 12-lead ECG
equipment designed to facilitate collection of cardiac safety data that is
subsequently provided to eRT for analysis.  eRT will perform digital
collection, measurement, interpretation, review, and distribution of cardiac
safety data through its EXPeRT(R) workflow enabled data handling technology,
the first solution in production that was designed explicitly to meet emerging
international regulatory guidance and technical standards.

"We are excited to have been selected to perform cardiac safety services for
these trials, which illustrate how the adoption of evolving regulatory guidance
is cutting across all segments and geographies of the new drug development
industry," said Scott Grisanti, senior vice president of business development
and chief marketing officer at eRT.  "eRT is unique in its ability to provide
the overall capacity and throughput required to address the demands of big
pharma's robust pipelines, while also being able to provide consultative
services and turnkey solutions required by emerging growth companies like the
Japanese sponsors for two of these important studies."

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com/) is a
provider of technology and services to the pharmaceutical, biotechnology and
medical device industries on a global basis.  The company is a market leader in
providing centralized core-diagnostic electrocardiographic (ECG) technology and
services to evaluate cardiac safety in clinical development. The company is
also a leader in providing technology and services to streamline the clinical
trials process by enabling its customers to automate the collection, analysis,
and distribution of clinical data in all phases of clinical development.

Statements included in this release may constitute forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995.
Such statements involve a number of risks and uncertainties such as competitive
factors, technological development, market demand, and the company's ability to
obtain new contracts and accurately estimate net revenues due to variability in
size, scope and duration of projects, and internal issues in the sponsoring
client. The sponsors may cancel these agreements at their sole discretion.  As
a result, actual results may differ materially from any financial outlooks
stated herein.  Further information on potential factors that could affect the
company's financial results can be found in the company's Reports on Forms 10-K
and 10-Q filed with the Securities and Exchange Commission. 

DATASOURCE: eResearchTechnology, Inc.



CONTACT:  Joan Sterlacci, eResearchTechnology, Inc., [phone]; or

Matt Hayden, Hayden Communications, [phone], for eResearchTechnology



Web site:  http://www.ert.com/ 

Copyright